診断用バイオマーカーの世界市場レポート 2025年

診断用バイオマーカー市場規模は、今後数年で急成長が見込まれます。2029年には年間平均成長率（CAGR）15.9％で1,365億7,000万米ドルに成長します。予測期間における成長の原動力は、リキッドバイオプシー技術の採用拡大、バイオマーカー研究への投資増加、精密医療への注目の高まり、神経変性疾患への応用拡大であると予想されます。主な動向には、人工知能と機械学習の発展、マルチオミクスアプローチの統合、ポイントオブケア診断ツールの開発、デジタルバイオマーカーへのシフト、ウェアラブル健康モニタリングデバイスの使用の増加、バイオマーカーの検証と標準化の重視の高まりなどがあります。

がんの罹患率の増加が診断用バイオマーカー市場の拡大を牽引しています。高齢化、ライフスタイルの変化、環境暴露、診断技術の進歩など、さまざまな要因ががんの有病率上昇に寄与しています。診断用バイオマーカーは、早期発見、正確な診断、個別化された治療アプローチを可能にし、最終的に患者の転帰を改善することで、がん発見に重要な役割を果たしています。例えば、米国を拠点とする非営利のがん擁護団体である米国がん協会は、2024年1月、がん罹患者数が2023年の195万8310人から201万1140人に増加し、2.19％増加したと報告しました。このようながん罹患率の増加が、診断用バイオマーカーの需要を引き続き促進しています。

診断用バイオマーカー市場の主要企業は、個別化治療アプローチを促進しながら患者の快適性とアクセス性を向上させるため、血液ベースのバイオマーカー検査などの非侵襲的検査法の開発を優先しています。血液ベースのバイオマーカー検査は、血液中の特定の生物学的マーカーを調べる診断ツールであり、低侵襲な方法でアルツハイマー病を含む疾患を検出または監視します。例えば、2023年7月、米国のライフサイエンス企業であるQuanterix Corporationは、初期の認知症状を有する患者のアルツハイマー病（AD）の診断において医療専門家を支援するために設計された血液ベースのバイオマーカー検査であるLucentADを発表しました。この検査は、ADの重要な指標である脳内のアミロイド病態に関連するバイオマーカーである、181残基でリン酸化されたタウタンパク質（p-Tau 181）の血漿レベルを測定します。LucentADは、脳脊髄液分析やアミロイド陽電子放射断層撮影などの従来の診断法に代わる、侵襲性が低く、より利用しやすい代替法を提供することで、アルツハイマー病が疑われる患者の評価プロセスを合理化することを目指しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界診断用バイオマーカーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の診断用バイオマーカー市場：成長率分析
• 世界の診断用バイオマーカー市場の実績：規模と成長, 2019-2024
• 世界の診断用バイオマーカー市場の予測：規模と成長, 2024-2029, 2034F
• 世界診断用バイオマーカー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の診断用バイオマーカー市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 安全性バイオマーカー
• 有効性バイオマーカー
• 検証バイオマーカー
• 世界の診断用バイオマーカー市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 代謝性疾患
• 神経疾患
• 世界の診断用バイオマーカー市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• がん調査機関
• 診断ラボ
• 世界の診断用バイオマーカー市場安全性バイオマーカーの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 毒性バイオマーカー
• 臓器特異的安全性バイオマーカー
• 薬剤誘発性傷害バイオマーカー
• 世界の診断用バイオマーカー市場有効性バイオマーカーの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 予測バイオマーカー
• 予後バイオマーカー
• 薬力学的バイオマーカー
• 世界の診断用バイオマーカー市場検証バイオマーカーの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ゲノムバイオマーカー
• プロテオームバイオマーカー
• メタボロミクスバイオマーカー

第7章 地域別・国別分析

• 世界の診断用バイオマーカー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の診断用バイオマーカー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 診断用バイオマーカー市場：競合情勢
• 診断用バイオマーカー市場：企業プロファイル
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • PerkinElmer Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Siemens Healthineers AG
• Merck KGaA
• Agilent Technologies Inc.
• Charles River Laboratories International Inc.
• Bio-Rad Laboratories Inc.
• Bruker Corporation
• Qiagen N.V.
• Myriad Genetics Inc.
• Meso Scale Diagnostics LLC
• EKF Diagnostics Holdings Plc
• Sino Biological Inc.
• Enzo Biochem Inc.
• Biomarker Technologies Inc.
• Cisbio Bioassays
• Signosis Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 診断用バイオマーカー市場2029：新たな機会を提供する国
• 診断用バイオマーカー市場2029：新たな機会を提供するセグメント
• 診断用バイオマーカー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A diagnostic biomarker is a biological indicator that aids in identifying a disease, distinguishing it from other conditions. This can include various types of findings, such as laboratory test results, radiological imaging, genetic markers, and physiological changes. Additionally, diagnostic biomarkers can offer insights into disease progression and the effectiveness of treatments.

The primary product types in diagnostic biomarkers include safety biomarkers, efficacy biomarkers, and validation biomarkers. Safety biomarkers are measurable indicators used to evaluate the potential risk of toxicity or adverse effects linked to medical treatments or environmental exposures. They help determine the safety of a therapy by monitoring biological responses that may signal harm. These biomarkers are applied in fields such as oncology, metabolic diseases, and neurological disorders, serving end users such as hospitals, cancer research institutes, and diagnostic laboratories.

The diagnostic biomarkers market research report is one of a series of new reports from The Business Research Company that provides diagnostic biomarkers market statistics, including diagnostic biomarkers industry global market size, regional shares, competitors with a diagnostic biomarkers market share, detailed diagnostic biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic biomarkers industry. This diagnostic biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diagnostic biomarkers market size has grown rapidly in recent years. It will grow from $65.25 billion in 2024 to $75.67 billion in 2025 at a compound annual growth rate (CAGR) of 16.0%. The growth during the historic period was driven by factors such as the increasing prevalence of chronic diseases, advancements in omics technologies, rising demand for personalized medicine, greater awareness of early disease detection, and the expanding use of non-invasive diagnostic methods.

The diagnostic biomarkers market size is expected to see rapid growth in the next few years. It will grow to $136.57 billion in 2029 at a compound annual growth rate (CAGR) of 15.9%. The growth in the forecast period is expected to be driven by the increasing adoption of liquid biopsy techniques, rising investments in biomarker research, a growing focus on precision medicine, and expanding applications in neurodegenerative diseases. Key trends include advancements in artificial intelligence and machine learning, the integration of multi-omics approaches, the development of point-of-care diagnostic tools, the shift toward digital biomarkers, the growing use of wearable health monitoring devices, and a heightened emphasis on biomarker validation and standardization.

The increasing incidence of cancer is driving the expansion of the diagnostic biomarkers market. Various factors, including an aging population, lifestyle changes, environmental exposures, and advancements in diagnostic technology, contribute to the rising prevalence of cancer. Diagnostic biomarkers play a vital role in cancer detection by enabling early identification, accurate diagnosis, and personalized treatment approaches, ultimately improving patient outcomes. For example, in January 2024, the American Cancer Society, a US-based nonprofit cancer advocacy organization, reported that the number of cancer cases had risen to 2,001,140 from 1,958,310 in 2023, marking a 2.19% increase. This growing prevalence of cancer continues to fuel the demand for diagnostic biomarkers.

Leading companies in the diagnostic biomarkers market are prioritizing the development of non-invasive testing methods, such as blood-based biomarker tests, to improve patient comfort and accessibility while facilitating personalized treatment approaches. A blood-based biomarker test is a diagnostic tool that examines specific biological markers in the blood to detect or monitor diseases, including Alzheimer's, in a minimally invasive manner. For instance, in July 2023, Quanterix Corporation, a US-based life sciences company, introduced LucentAD, a blood-based biomarker test designed to assist healthcare professionals in diagnosing Alzheimer's disease (AD) in patients with early cognitive symptoms. The test measures plasma levels of phosphorylated tau protein at the 181 residue (p-Tau 181), a biomarker linked to amyloid pathology in the brain, a key indicator of AD. By offering a less invasive and more accessible alternative to traditional diagnostic methods such as cerebrospinal fluid analysis or amyloid positron emission tomography, LucentAD aims to streamline the assessment process for suspected Alzheimer's patients.

In September 2024, Trinity Biotech, an Ireland-based clinical diagnostics company, acquired Metabolomics Diagnostics for approximately $1.3 million. This acquisition enhances Trinity Biotech's capabilities by integrating a strategically significant mass spectrometry platform with machine learning-driven bioinformatics. Metabolomics Diagnostics, also based in Ireland, specializes in developing novel biomarker-based diagnostic solutions for complex diseases.

Major players in the diagnostic biomarkers market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, PerkinElmer Inc., Siemens Healthineers AG, Merck KGaA, Agilent Technologies Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., Myriad Genetics Inc., Meso Scale Diagnostics LLC, EKF Diagnostics Holdings Plc, Sino Biological Inc., Enzo Biochem Inc., Biomarker Technologies Inc., Cisbio Bioassays, Signosis Inc., Epigenomics AG, LifeSign LLC, Banyan Biomarkers Inc., Biosims Technologies SAS.

North America was the largest region in the diagnostic biomarkers market in 2024. The regions covered in diagnostic biomarkers report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the diagnostic biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diagnostic biomarkers market consists of revenues earned by entities by providing services such as biomarker assay development and validation, biomarker-based diagnostic testing services, clinical trial support services, and data management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diagnostic biomarkers market also includes sales of biomarker assays, liquid biopsy kits, digital biomarkers, and genetic testing kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diagnostic Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diagnostic biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diagnostic biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The diagnostic biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Safety Biomarkers; Efficacy Biomarkers; Validation Biomarkers
• 2) By Application: Oncology; Metabolic Disease; Neurological Disease
• 3) By End User: Hospitals; Cancer Research Institutes; Diagnostic Labs
• Subsegments:
• 1) By Safety Biomarkers: Toxicity Biomarkers; Organ-Specific Safety Biomarkers; Drug-Induced Injury Biomarkers
• 2) By Efficacy Biomarkers: Predictive Biomarkers; Prognostic Biomarkers; Pharmacodynamic Biomarkers
• 3) By Validation Biomarkers: Genomic Biomarkers; Proteomic Biomarkers; Metabolomic Biomarkers
• Companies Mentioned: Johnson & Johnson Services Inc.; F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc.; Abbott Laboratories; PerkinElmer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Diagnostic Biomarkers Market Characteristics

3. Diagnostic Biomarkers Market Trends And Strategies

4. Diagnostic Biomarkers Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Diagnostic Biomarkers Growth Analysis And Strategic Analysis Framework

• 5.1. Global Diagnostic Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Diagnostic Biomarkers Market Growth Rate Analysis
• 5.4. Global Diagnostic Biomarkers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Diagnostic Biomarkers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Diagnostic Biomarkers Total Addressable Market (TAM)

6. Diagnostic Biomarkers Market Segmentation

• 6.1. Global Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Safety Biomarkers
• Efficacy Biomarkers
• Validation Biomarkers
• 6.2. Global Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Metabolic Disease
• Neurological Disease
• 6.3. Global Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Cancer Research Institutes
• Diagnostic Labs
• 6.4. Global Diagnostic Biomarkers Market, Sub-Segmentation Of Safety Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Toxicity Biomarkers
• Organ-Specific Safety Biomarkers
• Drug-Induced Injury Biomarkers
• 6.5. Global Diagnostic Biomarkers Market, Sub-Segmentation Of Efficacy Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Predictive Biomarkers
• Prognostic Biomarkers
• Pharmacodynamic Biomarkers
• 6.6. Global Diagnostic Biomarkers Market, Sub-Segmentation Of Validation Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genomic Biomarkers
• Proteomic Biomarkers
• Metabolomic Biomarkers

7. Diagnostic Biomarkers Market Regional And Country Analysis

• 7.1. Global Diagnostic Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Diagnostic Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Diagnostic Biomarkers Market

• 8.1. Asia-Pacific Diagnostic Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Diagnostic Biomarkers Market

• 9.1. China Diagnostic Biomarkers Market Overview
• 9.2. China Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Diagnostic Biomarkers Market

• 10.1. India Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Diagnostic Biomarkers Market

• 11.1. Japan Diagnostic Biomarkers Market Overview
• 11.2. Japan Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Diagnostic Biomarkers Market

• 12.1. Australia Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Diagnostic Biomarkers Market

• 13.1. Indonesia Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Diagnostic Biomarkers Market

• 14.1. South Korea Diagnostic Biomarkers Market Overview
• 14.2. South Korea Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Diagnostic Biomarkers Market

• 15.1. Western Europe Diagnostic Biomarkers Market Overview
• 15.2. Western Europe Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Diagnostic Biomarkers Market

• 16.1. UK Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Diagnostic Biomarkers Market

• 17.1. Germany Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Diagnostic Biomarkers Market

• 18.1. France Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Diagnostic Biomarkers Market

• 19.1. Italy Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Diagnostic Biomarkers Market

• 20.1. Spain Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Diagnostic Biomarkers Market

• 21.1. Eastern Europe Diagnostic Biomarkers Market Overview
• 21.2. Eastern Europe Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Diagnostic Biomarkers Market

• 22.1. Russia Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Diagnostic Biomarkers Market

• 23.1. North America Diagnostic Biomarkers Market Overview
• 23.2. North America Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Diagnostic Biomarkers Market

• 24.1. USA Diagnostic Biomarkers Market Overview
• 24.2. USA Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Diagnostic Biomarkers Market

• 25.1. Canada Diagnostic Biomarkers Market Overview
• 25.2. Canada Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Diagnostic Biomarkers Market

• 26.1. South America Diagnostic Biomarkers Market Overview
• 26.2. South America Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Diagnostic Biomarkers Market

• 27.1. Brazil Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Diagnostic Biomarkers Market

• 28.1. Middle East Diagnostic Biomarkers Market Overview
• 28.2. Middle East Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Diagnostic Biomarkers Market

• 29.1. Africa Diagnostic Biomarkers Market Overview
• 29.2. Africa Diagnostic Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Diagnostic Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Diagnostic Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Diagnostic Biomarkers Market Competitive Landscape And Company Profiles

• 30.1. Diagnostic Biomarkers Market Competitive Landscape
• 30.2. Diagnostic Biomarkers Market Company Profiles
  • 30.2.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. PerkinElmer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Diagnostic Biomarkers Market Other Major And Innovative Companies

• 31.1. Siemens Healthineers AG
• 31.2. Merck KGaA
• 31.3. Agilent Technologies Inc.
• 31.4. Charles River Laboratories International Inc.
• 31.5. Bio-Rad Laboratories Inc.
• 31.6. Bruker Corporation
• 31.7. Qiagen N.V.
• 31.8. Myriad Genetics Inc.
• 31.9. Meso Scale Diagnostics LLC
• 31.10. EKF Diagnostics Holdings Plc
• 31.11. Sino Biological Inc.
• 31.12. Enzo Biochem Inc.
• 31.13. Biomarker Technologies Inc.
• 31.14. Cisbio Bioassays
• 31.15. Signosis Inc.

32. Global Diagnostic Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Diagnostic Biomarkers Market

34. Recent Developments In The Diagnostic Biomarkers Market

35. Diagnostic Biomarkers Market High Potential Countries, Segments and Strategies

• 35.1 Diagnostic Biomarkers Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Diagnostic Biomarkers Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Diagnostic Biomarkers Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer